共查询到20条相似文献,搜索用时 31 毫秒
1.
目的探讨血清IGF-I浓度检测对估价冠心病患者左室功能及冠脉侧支循环状况的临床意义。方法应用放射免疫分析法检测4l例冠心病患者和15例正常人的血清IGF-I浓度;冠心病患者均行选择性冠状动脉造影,按Ren-trop法对侧支循环分级;左室造影测左室射血分数(LVEF)。结果冠心病患者组血清IGF-I浓度与正常对照组比较无显著性差异[(107.92±44.74)n/mLvs(113.05±33.65)n/mL,P>0.05]。冠心病组中,IGF-I水平≥120ng/mL的A亚组LVEF及Rentrop侧支循环分级均显著高于IGF-I水平<
120ng/mL的B亚组(LVEF0.62±0.13vs0.5l±0.12,P<0.01;Rentrop1.56±0.96vs0.12±0.33,P<0.001)。IGF-I水平与LVEF(r=0.45,P<0.001)及Rentrop侧支循环分级(r=0.74,P<0.001)均呈显著正相关。结论较高的IGF-I水平可能提示冠心病患者有较好的左室功能和冠脉侧支循环;血清IGF-I浓度检测可作为估价冠心病患者左室功能及冠脉侧支循环状况的指标。 相似文献
2.
大剂量阿托伐他汀预防对比剂肾病 总被引:3,自引:0,他引:3
Objective To compare the efficacy of high and low dose atorvastatin on preventing contrast induced nephropathy (CIN) in patients underwent diagnostic and therapeutic coronary intervention. Methods All patients received atorvastatin 10 mg/d on the basis of hydrated therapy (n =100) and high dose group received additional atorvastatin 80 nag at 12 to 24 hours before procedure (n =50). Scr, Ccr, blood β2-M, urine NAG/Cr, and urine osmolality before and after the procedure were compared between the groups. Results Baseline demographic characteristics and nephropathy risk factors were similar between groups. Cer was significantly reduced while blood β2-M and uric NAG/Cr were significantly increased in low dose group (all P < 0.05) . Blood β2-M in the high dose group was significantly lower than that in the low dose group at day 1 [(2.35±0.52) mg/L vs. (2.67±0.64) mg/L, P =0.008], day 3[(2.49±0.55)mg/L vs. (2.80±0.64) mg/L,P =0.011] and day 5[(2.29±0.53) mg/L vs. (2.56±0.66) nag/L, P = 0.026] post-procedure respectively; urine NAG/Cr in the high dose group was also significantly lower than that in the low dose group at day 1 [(1.19±0.30) U/mmol vs. (1.46±0.34) U/mmol, P < 0.001], day 3 [(1.30±0.30) U/mmol vs. (1.59±0.33) U/mmol, P < 0.001], and day 5 [(1.10±0.30) U/mmol vs. (1.34±0.35) U/mmol, P = 0.001] post-procedure respectively;Cer in the high dose group was significantly higher than that in the low dose group at day 1 [(73.69±20.99) mL/min vs. (65.19±18.72) mL/min,P =0.035], day 3[(64.04±15.82) ml/min vs. (56.79±14.50)ml/min,P =0.019] post-procedure respectively. Conclusion High dose atorvastatin use before angiography is superior than low dose atorvastatin on attenuating contrast induced renal dysfunction. 相似文献
3.
Objective To compare the efficacy of high and low dose atorvastatin on preventing contrast induced nephropathy (CIN) in patients underwent diagnostic and therapeutic coronary intervention. Methods All patients received atorvastatin 10 mg/d on the basis of hydrated therapy (n =100) and high dose group received additional atorvastatin 80 nag at 12 to 24 hours before procedure (n =50). Scr, Ccr, blood β2-M, urine NAG/Cr, and urine osmolality before and after the procedure were compared between the groups. Results Baseline demographic characteristics and nephropathy risk factors were similar between groups. Cer was significantly reduced while blood β2-M and uric NAG/Cr were significantly increased in low dose group (all P < 0.05) . Blood β2-M in the high dose group was significantly lower than that in the low dose group at day 1 [(2.35±0.52) mg/L vs. (2.67±0.64) mg/L, P =0.008], day 3[(2.49±0.55)mg/L vs. (2.80±0.64) mg/L,P =0.011] and day 5[(2.29±0.53) mg/L vs. (2.56±0.66) nag/L, P = 0.026] post-procedure respectively; urine NAG/Cr in the high dose group was also significantly lower than that in the low dose group at day 1 [(1.19±0.30) U/mmol vs. (1.46±0.34) U/mmol, P < 0.001], day 3 [(1.30±0.30) U/mmol vs. (1.59±0.33) U/mmol, P < 0.001], and day 5 [(1.10±0.30) U/mmol vs. (1.34±0.35) U/mmol, P = 0.001] post-procedure respectively;Cer in the high dose group was significantly higher than that in the low dose group at day 1 [(73.69±20.99) mL/min vs. (65.19±18.72) mL/min,P =0.035], day 3[(64.04±15.82) ml/min vs. (56.79±14.50)ml/min,P =0.019] post-procedure respectively. Conclusion High dose atorvastatin use before angiography is superior than low dose atorvastatin on attenuating contrast induced renal dysfunction. 相似文献
4.
Objective To compare the efficacy of high and low dose atorvastatin on preventing contrast induced nephropathy (CIN) in patients underwent diagnostic and therapeutic coronary intervention. Methods All patients received atorvastatin 10 mg/d on the basis of hydrated therapy (n =100) and high dose group received additional atorvastatin 80 nag at 12 to 24 hours before procedure (n =50). Scr, Ccr, blood β2-M, urine NAG/Cr, and urine osmolality before and after the procedure were compared between the groups. Results Baseline demographic characteristics and nephropathy risk factors were similar between groups. Cer was significantly reduced while blood β2-M and uric NAG/Cr were significantly increased in low dose group (all P < 0.05) . Blood β2-M in the high dose group was significantly lower than that in the low dose group at day 1 [(2.35±0.52) mg/L vs. (2.67±0.64) mg/L, P =0.008], day 3[(2.49±0.55)mg/L vs. (2.80±0.64) mg/L,P =0.011] and day 5[(2.29±0.53) mg/L vs. (2.56±0.66) nag/L, P = 0.026] post-procedure respectively; urine NAG/Cr in the high dose group was also significantly lower than that in the low dose group at day 1 [(1.19±0.30) U/mmol vs. (1.46±0.34) U/mmol, P < 0.001], day 3 [(1.30±0.30) U/mmol vs. (1.59±0.33) U/mmol, P < 0.001], and day 5 [(1.10±0.30) U/mmol vs. (1.34±0.35) U/mmol, P = 0.001] post-procedure respectively;Cer in the high dose group was significantly higher than that in the low dose group at day 1 [(73.69±20.99) mL/min vs. (65.19±18.72) mL/min,P =0.035], day 3[(64.04±15.82) ml/min vs. (56.79±14.50)ml/min,P =0.019] post-procedure respectively. Conclusion High dose atorvastatin use before angiography is superior than low dose atorvastatin on attenuating contrast induced renal dysfunction. 相似文献
5.
Objective To compare the efficacy of high and low dose atorvastatin on preventing contrast induced nephropathy (CIN) in patients underwent diagnostic and therapeutic coronary intervention. Methods All patients received atorvastatin 10 mg/d on the basis of hydrated therapy (n =100) and high dose group received additional atorvastatin 80 nag at 12 to 24 hours before procedure (n =50). Scr, Ccr, blood β2-M, urine NAG/Cr, and urine osmolality before and after the procedure were compared between the groups. Results Baseline demographic characteristics and nephropathy risk factors were similar between groups. Cer was significantly reduced while blood β2-M and uric NAG/Cr were significantly increased in low dose group (all P < 0.05) . Blood β2-M in the high dose group was significantly lower than that in the low dose group at day 1 [(2.35±0.52) mg/L vs. (2.67±0.64) mg/L, P =0.008], day 3[(2.49±0.55)mg/L vs. (2.80±0.64) mg/L,P =0.011] and day 5[(2.29±0.53) mg/L vs. (2.56±0.66) nag/L, P = 0.026] post-procedure respectively; urine NAG/Cr in the high dose group was also significantly lower than that in the low dose group at day 1 [(1.19±0.30) U/mmol vs. (1.46±0.34) U/mmol, P < 0.001], day 3 [(1.30±0.30) U/mmol vs. (1.59±0.33) U/mmol, P < 0.001], and day 5 [(1.10±0.30) U/mmol vs. (1.34±0.35) U/mmol, P = 0.001] post-procedure respectively;Cer in the high dose group was significantly higher than that in the low dose group at day 1 [(73.69±20.99) mL/min vs. (65.19±18.72) mL/min,P =0.035], day 3[(64.04±15.82) ml/min vs. (56.79±14.50)ml/min,P =0.019] post-procedure respectively. Conclusion High dose atorvastatin use before angiography is superior than low dose atorvastatin on attenuating contrast induced renal dysfunction. 相似文献
6.
Objective To compare the efficacy of high and low dose atorvastatin on preventing contrast induced nephropathy (CIN) in patients underwent diagnostic and therapeutic coronary intervention. Methods All patients received atorvastatin 10 mg/d on the basis of hydrated therapy (n =100) and high dose group received additional atorvastatin 80 nag at 12 to 24 hours before procedure (n =50). Scr, Ccr, blood β2-M, urine NAG/Cr, and urine osmolality before and after the procedure were compared between the groups. Results Baseline demographic characteristics and nephropathy risk factors were similar between groups. Cer was significantly reduced while blood β2-M and uric NAG/Cr were significantly increased in low dose group (all P < 0.05) . Blood β2-M in the high dose group was significantly lower than that in the low dose group at day 1 [(2.35±0.52) mg/L vs. (2.67±0.64) mg/L, P =0.008], day 3[(2.49±0.55)mg/L vs. (2.80±0.64) mg/L,P =0.011] and day 5[(2.29±0.53) mg/L vs. (2.56±0.66) nag/L, P = 0.026] post-procedure respectively; urine NAG/Cr in the high dose group was also significantly lower than that in the low dose group at day 1 [(1.19±0.30) U/mmol vs. (1.46±0.34) U/mmol, P < 0.001], day 3 [(1.30±0.30) U/mmol vs. (1.59±0.33) U/mmol, P < 0.001], and day 5 [(1.10±0.30) U/mmol vs. (1.34±0.35) U/mmol, P = 0.001] post-procedure respectively;Cer in the high dose group was significantly higher than that in the low dose group at day 1 [(73.69±20.99) mL/min vs. (65.19±18.72) mL/min,P =0.035], day 3[(64.04±15.82) ml/min vs. (56.79±14.50)ml/min,P =0.019] post-procedure respectively. Conclusion High dose atorvastatin use before angiography is superior than low dose atorvastatin on attenuating contrast induced renal dysfunction. 相似文献
7.
大剂量阿托伐他汀预防对比剂肾病 总被引:2,自引:0,他引:2
Objective To compare the efficacy of high and low dose atorvastatin on preventing contrast induced nephropathy (CIN) in patients underwent diagnostic and therapeutic coronary intervention. Methods All patients received atorvastatin 10 mg/d on the basis of hydrated therapy (n =100) and high dose group received additional atorvastatin 80 nag at 12 to 24 hours before procedure (n =50). Scr, Ccr, blood β2-M, urine NAG/Cr, and urine osmolality before and after the procedure were compared between the groups. Results Baseline demographic characteristics and nephropathy risk factors were similar between groups. Cer was significantly reduced while blood β2-M and uric NAG/Cr were significantly increased in low dose group (all P < 0.05) . Blood β2-M in the high dose group was significantly lower than that in the low dose group at day 1 [(2.35±0.52) mg/L vs. (2.67±0.64) mg/L, P =0.008], day 3[(2.49±0.55)mg/L vs. (2.80±0.64) mg/L,P =0.011] and day 5[(2.29±0.53) mg/L vs. (2.56±0.66) nag/L, P = 0.026] post-procedure respectively; urine NAG/Cr in the high dose group was also significantly lower than that in the low dose group at day 1 [(1.19±0.30) U/mmol vs. (1.46±0.34) U/mmol, P < 0.001], day 3 [(1.30±0.30) U/mmol vs. (1.59±0.33) U/mmol, P < 0.001], and day 5 [(1.10±0.30) U/mmol vs. (1.34±0.35) U/mmol, P = 0.001] post-procedure respectively;Cer in the high dose group was significantly higher than that in the low dose group at day 1 [(73.69±20.99) mL/min vs. (65.19±18.72) mL/min,P =0.035], day 3[(64.04±15.82) ml/min vs. (56.79±14.50)ml/min,P =0.019] post-procedure respectively. Conclusion High dose atorvastatin use before angiography is superior than low dose atorvastatin on attenuating contrast induced renal dysfunction. 相似文献
8.
Objective To compare the efficacy of high and low dose atorvastatin on preventing contrast induced nephropathy (CIN) in patients underwent diagnostic and therapeutic coronary intervention. Methods All patients received atorvastatin 10 mg/d on the basis of hydrated therapy (n =100) and high dose group received additional atorvastatin 80 nag at 12 to 24 hours before procedure (n =50). Scr, Ccr, blood β2-M, urine NAG/Cr, and urine osmolality before and after the procedure were compared between the groups. Results Baseline demographic characteristics and nephropathy risk factors were similar between groups. Cer was significantly reduced while blood β2-M and uric NAG/Cr were significantly increased in low dose group (all P < 0.05) . Blood β2-M in the high dose group was significantly lower than that in the low dose group at day 1 [(2.35±0.52) mg/L vs. (2.67±0.64) mg/L, P =0.008], day 3[(2.49±0.55)mg/L vs. (2.80±0.64) mg/L,P =0.011] and day 5[(2.29±0.53) mg/L vs. (2.56±0.66) nag/L, P = 0.026] post-procedure respectively; urine NAG/Cr in the high dose group was also significantly lower than that in the low dose group at day 1 [(1.19±0.30) U/mmol vs. (1.46±0.34) U/mmol, P < 0.001], day 3 [(1.30±0.30) U/mmol vs. (1.59±0.33) U/mmol, P < 0.001], and day 5 [(1.10±0.30) U/mmol vs. (1.34±0.35) U/mmol, P = 0.001] post-procedure respectively;Cer in the high dose group was significantly higher than that in the low dose group at day 1 [(73.69±20.99) mL/min vs. (65.19±18.72) mL/min,P =0.035], day 3[(64.04±15.82) ml/min vs. (56.79±14.50)ml/min,P =0.019] post-procedure respectively. Conclusion High dose atorvastatin use before angiography is superior than low dose atorvastatin on attenuating contrast induced renal dysfunction. 相似文献
9.
Objective To compare the efficacy of high and low dose atorvastatin on preventing contrast induced nephropathy (CIN) in patients underwent diagnostic and therapeutic coronary intervention. Methods All patients received atorvastatin 10 mg/d on the basis of hydrated therapy (n =100) and high dose group received additional atorvastatin 80 nag at 12 to 24 hours before procedure (n =50). Scr, Ccr, blood β2-M, urine NAG/Cr, and urine osmolality before and after the procedure were compared between the groups. Results Baseline demographic characteristics and nephropathy risk factors were similar between groups. Cer was significantly reduced while blood β2-M and uric NAG/Cr were significantly increased in low dose group (all P < 0.05) . Blood β2-M in the high dose group was significantly lower than that in the low dose group at day 1 [(2.35±0.52) mg/L vs. (2.67±0.64) mg/L, P =0.008], day 3[(2.49±0.55)mg/L vs. (2.80±0.64) mg/L,P =0.011] and day 5[(2.29±0.53) mg/L vs. (2.56±0.66) nag/L, P = 0.026] post-procedure respectively; urine NAG/Cr in the high dose group was also significantly lower than that in the low dose group at day 1 [(1.19±0.30) U/mmol vs. (1.46±0.34) U/mmol, P < 0.001], day 3 [(1.30±0.30) U/mmol vs. (1.59±0.33) U/mmol, P < 0.001], and day 5 [(1.10±0.30) U/mmol vs. (1.34±0.35) U/mmol, P = 0.001] post-procedure respectively;Cer in the high dose group was significantly higher than that in the low dose group at day 1 [(73.69±20.99) mL/min vs. (65.19±18.72) mL/min,P =0.035], day 3[(64.04±15.82) ml/min vs. (56.79±14.50)ml/min,P =0.019] post-procedure respectively. Conclusion High dose atorvastatin use before angiography is superior than low dose atorvastatin on attenuating contrast induced renal dysfunction. 相似文献
10.
Objective To compare the efficacy of high and low dose atorvastatin on preventing contrast induced nephropathy (CIN) in patients underwent diagnostic and therapeutic coronary intervention. Methods All patients received atorvastatin 10 mg/d on the basis of hydrated therapy (n =100) and high dose group received additional atorvastatin 80 nag at 12 to 24 hours before procedure (n =50). Scr, Ccr, blood β2-M, urine NAG/Cr, and urine osmolality before and after the procedure were compared between the groups. Results Baseline demographic characteristics and nephropathy risk factors were similar between groups. Cer was significantly reduced while blood β2-M and uric NAG/Cr were significantly increased in low dose group (all P < 0.05) . Blood β2-M in the high dose group was significantly lower than that in the low dose group at day 1 [(2.35±0.52) mg/L vs. (2.67±0.64) mg/L, P =0.008], day 3[(2.49±0.55)mg/L vs. (2.80±0.64) mg/L,P =0.011] and day 5[(2.29±0.53) mg/L vs. (2.56±0.66) nag/L, P = 0.026] post-procedure respectively; urine NAG/Cr in the high dose group was also significantly lower than that in the low dose group at day 1 [(1.19±0.30) U/mmol vs. (1.46±0.34) U/mmol, P < 0.001], day 3 [(1.30±0.30) U/mmol vs. (1.59±0.33) U/mmol, P < 0.001], and day 5 [(1.10±0.30) U/mmol vs. (1.34±0.35) U/mmol, P = 0.001] post-procedure respectively;Cer in the high dose group was significantly higher than that in the low dose group at day 1 [(73.69±20.99) mL/min vs. (65.19±18.72) mL/min,P =0.035], day 3[(64.04±15.82) ml/min vs. (56.79±14.50)ml/min,P =0.019] post-procedure respectively. Conclusion High dose atorvastatin use before angiography is superior than low dose atorvastatin on attenuating contrast induced renal dysfunction. 相似文献
11.
Objective To compare the efficacy of high and low dose atorvastatin on preventing contrast induced nephropathy (CIN) in patients underwent diagnostic and therapeutic coronary intervention. Methods All patients received atorvastatin 10 mg/d on the basis of hydrated therapy (n =100) and high dose group received additional atorvastatin 80 nag at 12 to 24 hours before procedure (n =50). Scr, Ccr, blood β2-M, urine NAG/Cr, and urine osmolality before and after the procedure were compared between the groups. Results Baseline demographic characteristics and nephropathy risk factors were similar between groups. Cer was significantly reduced while blood β2-M and uric NAG/Cr were significantly increased in low dose group (all P < 0.05) . Blood β2-M in the high dose group was significantly lower than that in the low dose group at day 1 [(2.35±0.52) mg/L vs. (2.67±0.64) mg/L, P =0.008], day 3[(2.49±0.55)mg/L vs. (2.80±0.64) mg/L,P =0.011] and day 5[(2.29±0.53) mg/L vs. (2.56±0.66) nag/L, P = 0.026] post-procedure respectively; urine NAG/Cr in the high dose group was also significantly lower than that in the low dose group at day 1 [(1.19±0.30) U/mmol vs. (1.46±0.34) U/mmol, P < 0.001], day 3 [(1.30±0.30) U/mmol vs. (1.59±0.33) U/mmol, P < 0.001], and day 5 [(1.10±0.30) U/mmol vs. (1.34±0.35) U/mmol, P = 0.001] post-procedure respectively;Cer in the high dose group was significantly higher than that in the low dose group at day 1 [(73.69±20.99) mL/min vs. (65.19±18.72) mL/min,P =0.035], day 3[(64.04±15.82) ml/min vs. (56.79±14.50)ml/min,P =0.019] post-procedure respectively. Conclusion High dose atorvastatin use before angiography is superior than low dose atorvastatin on attenuating contrast induced renal dysfunction. 相似文献
12.
目的 本文旨在探讨血纤维蛋白原浓度在不稳定型心绞痛不同危险分层中的变化。方法 将 162例入选的不稳定型心绞痛患者 ,分成高危组 ( n=3 4)、中危组 ( n=5 8)及低危组 ( n=70 ) ,同时测定三组血浆纤维蛋白原及心脏肌钙蛋白 T( c Tn T)浓度。结果 三组血纤维蛋白原浓度有显著性差异 ,随危险分层的增高 ,血纤维蛋白原浓度有增加的趋势 [( 3 98.3 6± 12 6.3 2 ) m g/ dl( 42 5 .75± 14 3 .5 2 ) m g/ dl及 ( 473 .15± 160 .61) mg/ dl,P<0 .0 1]。结论 血纤维蛋白原浓度有助于不稳定型心绞痛的危险分层 ;血纤维蛋白原升高提示 ,不稳定型心绞痛患者危险分层高 ,有较强的血栓形成趋势。 相似文献
13.
目的探讨C反应蛋白(CRP)作为系统炎症因子在心房颤动发生和发展中的作用。方法入选98例患者将其分为正常对照组(n=34),阵发性心房颤动组(n=31)和持续性心房颤动组(n=33),比较各组CRP水平。结果心房颤动组CRP水平(18.5±4.4)mg/L比正常对照组(4.1±1.3)mg/L高,P<0.01;在心房颤动组中持续性心房颤动组血清中CRP(20.2±5.4)mg/L高于阵发性心房颤动组(15.5±4.0)mg/L,P<0.01;阵发性心房颤动组(20.2±5.4)mg/L高于正常对照组(4.1±1.3)mg/L,P<0.01。不同原因引起的心房颤动CRP不同,冠心病最高,其次为高血压,心肌病最低。结论CRP在心房颤动患者明显升高,其代表的炎症状态在心房颤动的发生和持续中起一定作用。 相似文献
14.
目的观察老年高血压患者血清胱蛋白酶抑制剂C(Cyst-c)浓度对检出早期肾损害的价值.方法对412例老年高血压患者同时测血Cyst-c和血肌酐(Cr)浓度,并与正常对照组对照.结果412例老年高血压患者中早期肾损害197例(占47.82%),肾功能不全24例(5.82%),肾功能正常191例(46.36%).在早期肾损害组血Cyst-c浓度明显高于对照组[(2.3土0.8 vs 0.9±0.2)mg/L,P<0.01)],而血Cr浓度两组无显著性差异[(86.6±12.7 vs 81.0±10.5)μmol/L,P>0.05].结论老年高血压患者中,早期肾损害占47.82%,很常见.血Cyst-c能检出血Cr不能检出的早期肾损害. 相似文献
15.
C反应蛋白与心房颤动的关系 总被引:1,自引:0,他引:1
目的探讨C反应蛋白(CRP)作为系统炎症因子在心房颤动发生和发展中的作用。方法入选98例患者将其分为正常对照组(n=34)、阵发性房颤组(n=31)和持续房颤组(n=33),比较各组C反应蛋白水平。结果心房颤动组CRP水平[(1.85±0.44)mg/d]比正常对照组的水平[(0.41±0.13)mg/d]高,P<0.01;在心房颤动组中持续房颤组血清中CRP[(2.02±0.54)mg/d]高于阵发性房颤组[(1.55±0.40)mg/d],P<0.01,阵发性房颤组[(2.02±0.54)mg/d]高于正常对照组(0.41±0.13)mg/dl,P<0.01。并且不同原因引起的房颤CRP不同,冠心病最高,其次为高血压,心肌病最低。结论CRP在心房颤动患者中明显升高,说明炎症状态在心房颤动的发生和持续中起一定作用。 相似文献
16.
十二指肠溃疡与血浆肽类胃肠激素变化 总被引:1,自引:1,他引:0
目的探讨胃肠激素含量变化与十二指肠溃疡的发生、发展的关系.方法十二指肠溃疡活动期(DU)患者共280例,男229例,女51例,平均36.12岁;健康成年人316例为对照组,男198例,女118例,平均40.29岁.采用RIA方法测定空腹血浆促胃液素(GAS)、胃动素(MTL)、内皮素(ET)、肾上腺髓质素(AM)、甘丙素(GAL)和降钙素基因相关肽(CGRP)水平.结果 DU患者空腹血浆GAS,MTL,ET和AM水平(pg/mL)较对照组明显升高,分别为74.64±18.50(n=178)与63.33±38.09(n=147),P<0.01;496.80±102.11(n=30)与314.60±53.50(n=50),P<0.05;41.12±3.73(n=16)与6.35±0.44(n=38),P<0.01;115.51±27.01(n=15),P<0.02.然而,二组血浆GAL和CGRP含量比较则表现为DU患者显著低于健康人,分别为1.84±0.63(n=21)与9.36±0.94(n=29)和3.89±1.58(n=20)与32.99±7.29(n=27),二者皆P<0.001结论本文检测六种胃肠激素的血浆浓度,其含量变化可能在人体正常生理稳态调节中以及DU的发病和愈合过程中起着重要作用. 相似文献
17.
同型半胱氨酸作用于正常个体血小板凝聚反应的体外研究 总被引:2,自引:1,他引:2
目的 研究人体血清或血浆同型半胱氨酸 (HCY)的升高与血小板高凝状态的关系。方法 全血或浓缩血小板与不同浓度的 HCY于 37℃ (用于血小板凝聚检测 )或 2 2~ 2 5℃ [用于血小板纤维原结合及 P-选择素 (P- selectin)表达的检测 ]作用 15 min,后应用血小板凝聚仪和流式细胞仪分别检测 HCY对血小板活性的作用。结果 HCY在浓度 30 μm ol/ L 时能增加一磷酸腺苷 (ADP)和胶原诱导的全血和浓缩血小板凝聚反应 [(3.0± 0 .8) Ω/ min vs(5 .0± 2 .0 ) Ω/ m in,P<0 .0 5 ,n=9和 (8.5± 1.5 ) Ω/ min vs(11± 2 .5 ) Ω/ min,P<0 .0 5 ,n=6 ],但在浓度 10 0 0μm ol/ L时却抑制 ADP和胶原诱导的全血和浓缩血小板凝聚反应 [(7.0± 4 .0 )Ω vs (3.6± 2 .6 )Ω和 (6 .8± 2 .2 )Ω vs (4.1± 3.3)Ω ,P<0 .0 5 ,n=9],血小板凝聚性的改变并不伴随血小板纤维原结合及 P- selectin表达的变化。结论 体外实验表明 HCY能协同促进已激活的血小板凝聚反应 ,可能是 HCY与体内血栓形成有关的机理之一 相似文献
18.
《高血压杂志》2007,(5)
慢性肾病(CKD)病人的正规治疗应包括血管紧张素转换酶抑制剂(ACEI)与血管紧张素Ⅱ受体阻滞剂(ARB),CKD病人常有交感神经活性增强。该文测定一组CKD病人肌肉交感神经活性(MS-NA),考查ACEI与ARB治疗是否能使增高的MS-NA下降。74例CKD病人(肌酐清除率54±31mL/min)未用上述降压药,只用利尿剂的情况下,测定MSNA、BP、血浆肾素活性。亚组31例在用药(依那普利10mg、氯沙坦100mg或依普鲁沙坦600mg)6周以后,再测定上述指标。病人与对照组(n=82)比较,平均动脉压较高[(113±13)vs(89±7)mm Hg],MSNA[(31±13)vs(19±7)冲动数/min],… 相似文献
19.
目的探讨高敏C反应蛋白(hsCRP)与急性冠状动脉综合征(ACS)病变程度的关系及临床意义。方法测定经冠状动脉造影证实为ACS患者(n=54)的血清hsCRP浓度,与正常对照组(n=18)的hsCRP浓度相比较,分析二组间及ACS组中,冠状动脉病变支数与相应hsCRP浓度的关系。结果hsCRP浓度在对照组,不稳定型心绞痛组,急性心肌梗死组依次增高,分别为(1.474±1.063)mg/L,(5.753±4.168)mg/L,(12.140±6.679)mg/L。在ACS组中,单支病变组,双支病变组,三支病变组,其hsCRP浓度也依次增高,分别为(5.513±2.458)mg/L,(8.321±4.785)mg/L,(12.423±4.104)mg/L。结论hsCRP可作为ACS患者判断病情严重程度及预后的指标。 相似文献
20.
胆石性胆道梗阻病程中一氧化氮、内皮素的变化及意义 总被引:5,自引:3,他引:2
目的了解NO,ET在胆石性胆道梗阻病程演进过程中的作用及其临床意义.方法对无急性胆管炎的150例胆石胆道梗阻患者,按梗阻性黄疸发生时间(Ⅰ组:67例,黄疸时间4.24 d±1.74 d.Ⅱ组:37例,黄疸时间10.41 d±1.82 d.Ⅲ组:46例,黄疸时间38.02 d±29.67 d)和血内毒素检测结果(内毒素阳性组112例,内毒素阴性组33例)分组比较NO,ET内毒素和肝功能变化关系,同时检测20例正常人做对照.结果在梗阻性黄疸Ⅰ,Ⅱ,Ⅲ组和正常对照组,各项检测值依序为:清蛋白(g/L):39.66±4.50,35.67±5.19,34.40±7.83,42.91±2.87(四组比较:F=15.4107,P<0.01);ALT(U/L):123.45±154.64,139.04±192.59,160.87±114.03,24.65±12.61(F=4.2348,P<0.01);总胆红素(μmol/L):97.39±116.61,108.67±113.84,105.88±102.51,12.99±4.29(F=4.3955,P<0.01);直接胆红素(μmol/L):25.06±20.38,30.18±21.71,8.12±33.38,2.85±1.31(F=10.5229,P<0.01);NO(μmol/L):70.00±48.97,82.52±41.24,73.63±48.15,25.06±7.22(F=7.9100,P<0.01);ET1(pg/mL):55.18±25.46,69.14±45.60,56.48±38.91,39.0±8.19(F=3.5837,P<0.05);内毒素(Eu/mL):0.0533±0.0937,0.0954±0.0970,0.1175±0.1237,……(F=5.2084,P<0.01).对各时间段梗阻性黄疸患者各指标行相关分析发现:Ⅰ组NO与ET1、清蛋白呈负相关(γET1=-0.289,P<0.05;γA=-0.348,P<0.01),与内毒素、总胆红素呈正相关(γet=0.774,P<0.01;γtb=0.368,P<0.01).Ⅱ组NO与ET1、清蛋白呈负相关(γET1=-0.417,γA=-0.438,P均=0.01);内毒素与ET1、直接胆红素呈正相关(γET1=0.385,γdb=0.364,P均<0.05).Ⅲ组NO与内毒素呈正相关(γ=0.406,P<0.01);NO与ET1无统计学意义的相关关系按血内毒素检测结果比较见,内毒素阳性组和阴性组黄疸时间(18.95 d±24.49 d对8.33 d±8.84 d,t=3.8191,P<0.01)、清蛋白(g/L,36.17±6.68对39.87±4.21,t=3.8261,P<0.01)、直接胆红素(μmol/L,32.89±27.32对23.21±20.05,t=2.2309,P<0.05)、NO(μmol/L,83.62±47.95,44.03±28.19,t=5.9283,P<0.01)有统计学意义的差别;相关分析见:内毒素阴性组,NO与清蛋白、ET1呈负相关(γA=-0.421,P<0.05;γET1=-0.527,P<0.01).内毒素阳性组,NO与内毒素呈正相关(γ=0.437,P<0.01)与ET1无统计学意义的相关关系结论①胆石性胆道梗阻时内毒素等导致NO与ET1的协调关系发生紊乱、NO的正常保护机制受损,这在胆道梗阻所致肝功能衰竭、肝纤维化、肝肾综合征发病机制中可能起了重要作用.②NO与ET1原有的负相关关系,随着黄疸时间延长、肝功能损害程度加重、内毒素血症出现而消失,提示检测比较NO/ET1的变化关系,有可能作为了解肝细胞损害程度、肝储备功能的参考指标. 相似文献